Efficacy and Safety of the Additional Bepridil Treatment in Patients With Atrial Fibrillation Refractory to Class I Antiarrhythmic Drugs

• Miyaji Kohei

  Department of Cardiovascular Medicine, Okayama University Graduated School of Medicine, Density and Pharmaceutical Science

• Tada Hiroshi

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Fukushima Kusano Kengo

  Department of Cardiovascular Medicine, Okayama University Graduated School of Medicine, Density and Pharmaceutical Science

• Hashimoto Tohru

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Kaseno Kenichi

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Hiramatsu Shigeki

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Tadokoro Kazuyoshi

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Naito Shigeto

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Nakamura Kazufumi

  Department of Cardiovascular Medicine, Okayama University Graduated School of Medicine, Density and Pharmaceutical Science

• Oshima Shigeru

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Taniguchi Koichi

  Division of Cardiology, Gunma Prefectural Cardiovascular Center

• Ohe Tohru

  Department of Cardiovascular Medicine, Okayama University Graduated School of Medicine, Density and Pharmaceutical Science

Abstract

Background Bepridil has multiple ion-channel blocking effects and is expected to be useful for managing atrial fibrillation (AF). The purpose of this study was to clarify the efficacy and safety of additional treatment with bepridil in patients with AF who had been treated with class I antiarrhythmic drugs (AADs). Methods and Results Bepridil (50-200 mg/day) was given to 76 patients with either paroxysmal (n=49) or persistent AF (n=27). All patients had been treated with class I AADs (1.9±0.9 drugs/patient) that failed to control the AF. With the addition of bepridil, the frequency of symptomatic AF episodes decreased to less than 10% in 38 (78%) patients with paroxysmal AF, and sinus rhythm was restored within 3 months and maintained during the follow-up in 20 (74%) patients with persistent AF. Efficacy was usually obtained with a small to moderate dose (50-150 mg/day) of bepridil. During a mean follow-up period of 27±22 months, no potential complications occurred in any of the patients. Conclusions The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation. (Circ J 2007; 71: 1250 - 1257)<br>

Journal

• Circulation Journal

  Circulation Journal 71 (8), 1250-1257, 2007

  The Japanese Circulation Society

Keywords

• Antiarrhythmic drugs
• Atrial fibrillation
• Bepridil

Details

• CRID: 1390001205104617216
• NII Article ID: 110006368851
• NII Book ID: AA11591968
• DOI: 10.1253/circj.71.1250
• ISSN: 13474820
• ISSN: 13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/71/8/71_8_1250/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2008033335
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed